Vanda Pharma expects near-term boost from BYSANTI launch
Report says two new drugs, NEREUS and BYSANTI, were approved, and BYSANTI’s launch plus a Fanapt switch strategy are expected to support near-term revenue, with a stated psychiatry revenue target by 2030.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.